Lonza to Expand U.K. Facility

Lonza says it will invest £16 million ($26 million) to expand its biopharmaceutical manufacturing facility at Slough, U.K., in order to respond to a broader range of customer projects and strengthen its global network of biologics development and manufacturing. The expansion project is expected to be completed by the end of 2012. The Slough site develops and manufactures antibodies and therapeutic proteins used in the clinical stages of drug development and ongoing commercial supply of marketed biopharmaceutical products. With the new investment, Lonza will...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers